- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) received written notice from Janssen, a unit of Johnson & Johnson (NYSE:JNJ), to terminate their rights to JNJ-75220795, now called ARO-PNPLA3, under the October 2018 research collaboration and option agreement.
- The companies are working to transition the program and associated data to Arrowhead.
- ARO-PNPLA3 is an investigational RNA interference (RNAi) therapeutic developed using Arrowhead’s proprietary TRiM platform and designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) for non-alcoholic steatohepatitis (NASH).
- ARO-PNPLA3 is currently in Phase 1 clinical study.
- After a single dose in Phase 1 clinical study, ARO-PNPLA3 showed a dose-dependent mean reduction in liver fat of up to 40% in patients homozygous for the I148M mutation.
- No apparent treatment-emergent increases in triglycerides or LDL cholesterol.
- In 2021, Arrowhead announced a deal with GSK plc (NYSE: GSK), under which GSK will develop and market Arrowhead’s potential treatment for patients with fatty liver disease NASH.
- At that time, the drug candidate ARO-HSD is currently in an early-to-mid stage trial for NASH.
- Price Action: ARWR shares are down 0.83% at $33.39 on the last check Wednesday.
GameStop Up Triple Digits Premarket: Is 2021 Meme Stock Rally Back?
GameStop and AMC stocks surge by 147% and 121% respectively, driven by retail investors coordinating through online platforms. Market volatility expected.
